Acute Myeloid Leukemia MedDRA version: 14.1 Level: LLT Classification code 10001941 Term: AML System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Conditions
Interventions
Trade Name: Sutent
Pharmaceutical Form: Capsule, hard
Trade Name: Sutent
Pharmaceutical Form: Capsule, hard
Sponsors
University Medical Center Hamburg-Eppendorf
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: • Patients with primary or secondary acute myeloid leukemia (any FAB type, except M3). • No prior systemic chemotherapy for AML except hydroxyurea. Cytoreductive therapy with hydroxyurea is recommended if WBC is > 50.000/µl, but should cease at least one day prior to starting study medication • Patient age equal or of greater than 60 years • Patients must have FLT3 mutated AML, either ITD or kinase domain mutations • ECOG Performance score 3 or less (Karnofsky Performance Score >40%). • Life expectancy more than four weeks. • Adequate hepatic and renal function, as defined by serum transaminases =65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: • Treatment with any investigational agent within four weeks. • Known HIV infection • Presence of any medical or psychiatric condition which may limit full compliance with the study, including but not limited to: • Presence of CNS leukaemia • Unresolved toxicity from previous anti-cancer therapy or incomplete recovery from surgery. • Any of the following within the 12 months prior to study drug administration: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, pulmonary embolism, deep vein thrombosis, or other thromboembolic event. • Current treatment with therapeutic doses of anticoagulant (low dose Coumadin up to 2 mg PO daily for deep vein thrombosis prophylaxis is allowed). • Hypertension that cannot be controlled by medications (>150/100 mmHg despite optimal medical therapy). • Pre existing thyroid abnormality of thyroid function that cannot be maintained in the normal range with medication. • Ongoing cardiac dysrhythmias of NCI CTCAE Grade =2, atrial fibrillation of any Grade, or prolongation of the QTc interval to >450 msec for males or >470 msec for females. • Other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the investigator would make the patient inappropriate for entry into this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To assess the tolerability and safety of 2 dose levels of SU11248 in combination with standard induction and consolidation therapy;Secondary Objective: To document any anti-AML activity of SU11248 in combination with standard induction and consolidation therapy;Primary end point(s): Definition of a recommended Phase III dose and determination CTC version 3.0 grade 3-5 non-hematological toxicities of SU11248 in combination with standard induction and consolidation chemotherapy | — |
Countries
Germany
Outcome results
None listed